A stringent regulatory authority is a regulatory authority which is: a) a member of the
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), being the
European Commission, the US
Food and Drug Administration and the
Ministry of Health, Labour and Welfare of Japan also represented by the
Pharmaceuticals and Medical Devices Agency (as before 23 October 2015); or b) an ICH observer, being the
European Free Trade Association, as represented by
Swissmedic, and
Health Canada (as before 23 October 2015); or a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement, including Australia, Iceland, Liechtenstein and Norway (as before 23 October 2015). The idea is that countries with non-SRA drug authorities can use accelerated process to facilitate approval (registration or marketing authorization) of medicines, including vaccines and
biologics, which have already been approved by SRAs. == Replacement by the WHO-Listed Authority (WLA) framework ==